Candidemia and Invasive Candidiasis
Bloodstream infection (candidemia) and deep-tissue infections caused by Candida species. A serious healthcare-associated infection with mortality rates of 30-50%. Most commonly caused by C. albicans, C. glabrata, and C. tropicalis. Requires systemic antifungal therapy.
Quick Answer
What it is
Bloodstream infection (candidemia) and deep-tissue infections caused by Candida species. A serious healthcare-associated infection with mortality rates of 30-50%.
Key findings
- Grade A: HSCT Candida Prophylaxis (Micafungin (Mycamine))
- Grade A: Esophageal Candidiasis (Micafungin (Mycamine))
- Grade A: Invasive Candidiasis/Candidemia (Micafungin (Mycamine))
Safety
- No serious clinical or laboratory adverse events.
- May avoid need for central venous catheter.
ℹ️ Quick Facts
Quick Facts: Candidemia and Invasive Candidiasis
- Supplements Studied:4
4 supps · 17 outcomes
Detailed Outcomes
|
A
HSCT Candida Prophylaxis
Phase 3 RCT: Micafungin superior to fluconazole for prophylaxis of invasive Candida infections in HSCT recipients. Only echinocandin FDA-approved for this indication. Significantly reduced breakthrough fungal infections.
large↓Improves
A
Esophageal Candidiasis
Clinical trials: Efficacy comparable to fluconazole in esophageal candidiasis treatment. FDA-approved indication. Endoscopic cure rates similar to standard therapy.
moderate↑Improves
A
Invasive Candidiasis/Candidemia
Phase 3 trials: Excellent clinical and microbiological efficacy in primary treatment of invasive candidiasis. Comparable to caspofungin and liposomal amphotericin B. FDA-approved for candidemia.
moderate↑Improves
A
Safety Profile (Pooled Analysis)
Pooled analysis of 17 trials (n=3028): Favorable clinical safety profile similar to other echinocandins. Well tolerated across treatment and prophylaxis indications. Low discontinuation rates.
large↑Improves
B
Pediatric Efficacy
Approved for pediatric use. Effective for prophylaxis and treatment in children including neonates. Weight-based dosing (2-4 mg/kg). Scientific evidence supports safety and efficacy in pediatric populations.
moderate↑Improves
A
Treatment Success (vs Fluconazole)
Phase 3 RCT: 76% anidulafungin vs 60% fluconazole achieved treatment success (95% CI 4-27%, P=0.01). Superior efficacy in invasive candidiasis and candidemia. FDA approval 2006.
moderate↑Improves
A
Dose-Ranging Efficacy
Phase 2 study (n=123): Success rates 84%, 90%, 89% at 50, 75, 100 mg respectively. High efficacy across dose range. 100 mg daily selected for Phase 3.
large↑Improves
A
Activity vs Fluconazole-Resistant Candida
In vitro: 99% of 315 fluconazole-resistant Candida isolates susceptible to anidulafungin (MIC <=1 ÎĽg/ml). Important option for azole-resistant infections.
large↑Improves
B
Safety in Organ Impairment
No dose adjustment needed in hepatic or renal impairment. Non-CYP450 metabolism minimizes drug interactions. Well tolerated with low discontinuation rates.
moderate↑Improves
A
Day-14 Global Cure
ReSTORE Phase 3 (n=187): 59% rezafungin vs 61% caspofungin achieved global cure at day 14 (EMA primary endpoint). Noninferiority demonstrated. First new echinocandin approved in >10 years.
moderate↑Improves
A
30-Day All-Cause Mortality
ReSTORE Phase 3: 24% rezafungin vs 21% caspofungin mortality at day 30 (FDA primary endpoint). Noninferior within 20% margin. Similar safety profile to other echinocandins.
none
A
Efficacy by Candida Species
Species subanalysis: Effective against C. albicans (42%), C. glabrata (26%), and C. tropicalis (20%). Consistent efficacy across major Candida species causing invasive disease.
moderate↑Improves
B
Weekly Dosing Convenience
Unique weekly dosing (vs daily for caspofungin/micafungin) enables outpatient parenteral therapy. May avoid need for central venous catheter. Improves patient convenience and reduces healthcare resource use.
moderate↑Improves
A
Esophageal Candidiasis Response
Phase 2 trial (n=128): 85.1% caspofungin vs 66.7% amphotericin B achieved symptom and endoscopic improvement at 2 weeks. Superior efficacy with better tolerability.
large↑Improves
A
Invasive Candidiasis Efficacy
Approved for candidemia and invasive Candida infections including intra-abdominal abscesses, peritonitis, pleural cavity infections. Established efficacy in multiple trials. First-line option.
moderate↑Improves
A
Activity vs Fluconazole-Resistant Candida
In vitro: MIC90 0.5-1 ug/ml against 157 fluconazole-resistant isolates. Retained activity against 3,959 clinical Candida isolates. Critical option for azole-resistant infections.
large↑Improves
A
Safety and Tolerability
RCTs (n=263): Only 2% discontinued due to drug-related AEs. No serious clinical or laboratory adverse events. Well tolerated in 623 patients studied. Infusion reactions rare.
large↑Improves